Recent research brings hope to advanced breast cancer patients with a potential new treatment. Researchers are exploring the efficacy of trastuzumab rezetecan for patients with ERBB2-low metastatic breast cancer, characterized by low levels of HER2, a protein that can enhance cancer cell growth.
Clinical Trial Findings
The HORIZON-Breast06 phase 3 clinical trial investigated whether trastuzumab rezetecan is more effective than standard chemotherapy for this cancer type. Involving 551 female patients across 73 hospitals in China, the trial randomly assigned participants to receive either the drug intravenously every three weeks or the physician’s choice of chemotherapy. The study spanned from June 2023 to August 2025.
The study revealed that the median time without tumor growth for patients on the drug was 16.4 months, compared to 6.8 months for those on chemotherapy. This significant delay in cancer progression indicates that patients on the drug could experience over a year without cancer growth reoccurrence.
Survival and Response Rates
Trastuzumab rezetecan recipients demonstrated a 73% reduced risk of cancer worsening or death compared to chemotherapy patients. The drug showed benefits for both hormone receptor-positive and hormone receptor-negative breast cancer.
Tumor shrinkage occurred in 75.5% of patients taking the drug, compared to 41.2% of chemotherapy patients. At 12 months, survival rates were 90.6% for drug recipients and 81.4% for those on chemotherapy.
Expert Insights
The study’s findings, published in JAMA, concluded a significant progression-free survival benefit of the drug over chemotherapy for patients with ERBB2-low advanced breast cancer. Texas-based breast surgical oncologist, Loren Rourke, described the results as “incredibly encouraging,” noting the importance of extending life when living with advanced breast cancer.
Side Effects and Concerns
Despite its benefits, the drug was associated with serious side effects, including anemia and other blood disorders. Over 84% of patients experienced significant side effects, necessitating dose modifications, although these were generally manageable. Rourke emphasized the need to balance more time without cancer progression against potential impacts on life quality.
Experts agree on the necessity for further research. “There are still important questions to answer,” Rourke said, pointing out the need to determine if the treatment extends patient lifespans, not merely delays cancer progression.
These findings represent positive steps for breast cancer treatment, providing genuine hope for longer, disease-free periods.
The Impact of Arbitration on Health Insurance Costs 
The Growing Impact of Cannabis Use on Families 
Potential Conflict of Interest In Federal Health Agency 
Data Centers Spark Health and Political Concerns in Arizona 
Social Media Habits and Mental Health in Adolescents 
HHS Proposal to Regulate Compounded Peptide Drugs